Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.

Also called NCT01932970

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 158 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01932970
  • EudraCT 2013-000964-28
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01932970. Allocation not applicable; no masking; primary purpose treatment. Start 2013-08-12 (actual); primary completion 2014-01-14 (actual). Results posted on 2017-04-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
Condition
Hyperparathyroidism, Secondary
Intervention (Drug)
Etelcalcetide
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01932970
Content hash
2131138f2d9915d671c93a11fcffac6ef0c43522e2c21e8ebdf9395a18b4f2df